Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.

Microarray analysis with 40 000 cDNA gene chip arrays determined differential gene expression profiles (GEPs) in CD34(+) marrow cells from myelodysplastic syndrome (MDS) patients compared with healthy persons. Using focused bioinformatics analyses, we found 1175 genes significantly differentially expressed by MDS versus normal, requiring a minimum of 39 genes to separately classify these patients. Major GEP differences were demonstrated between healthy and MDS patients and between several MDS subgroups: (1) those whose disease remained stable and those who subsequently transformed (tMDS) to acute myeloid leukemia; (2) between del(5q) and other MDS patients. A 6-gene "poor risk" signature was defined, which was associated with acute myeloid leukemia transformation and provided additive prognostic information for International Prognostic Scoring System Intermediate-1 patients. Overexpression of genes generating ribosomal proteins and for other signaling pathways was demonstrated in the tMDS patients. Comparison of del(5q) with the remaining MDS patients showed 1924 differentially expressed genes, with underexpression of 1014 genes, 11 of which were within the 5q31-32 commonly deleted region. These data demonstrated (1) GEPs distinguishing MDS patients from healthy and between those with differing clinical outcomes (tMDS vs those whose disease remained stable) and cytogenetics [eg, del(5q)]; and (2) molecular criteria refining prognostic categorization and associated biologic processes in MDS.

[1]  M. Carroll Taking aim at protein translation in AML. , 2009, Blood.

[2]  K. B. McIntosh,et al.  How common are extraribosomal functions of ribosomal proteins? , 2009, Molecular cell.

[3]  L. Hood,et al.  Dysregulated gene expression networks in human acute myelogenous leukemia stem cells , 2009, Proceedings of the National Academy of Sciences.

[4]  M. Stearns,et al.  RPS2: a novel therapeutic target in prostate cancer , 2009, Journal of experimental & clinical cancer research : CR.

[5]  P. Kincade,et al.  Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. , 2009, Experimental hematology.

[6]  Alan H Beggs,et al.  Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. , 2008, American journal of human genetics.

[7]  E. Donadi,et al.  Transcriptional changes in U343 MG-a glioblastoma cell line exposed to ionizing radiation , 2008, Human & experimental toxicology.

[8]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Diamandis,et al.  Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. , 2008, Clinical chemistry.

[10]  P. Pelicci,et al.  A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth , 2008, Nature Cell Biology.

[11]  M. Cazzola,et al.  Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes , 2008, British journal of haematology.

[12]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[13]  M. Cazzola,et al.  Gene expression profiling of CD34+ cells in patients with the 5q− syndrome , 2007, British journal of haematology.

[14]  G. Sotiropoulou,et al.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. , 2007, Biochimica et biophysica acta.

[15]  W. Berdel,et al.  The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia , 2007, Leukemia.

[16]  B. Sander,et al.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.

[17]  Julie A. Wilkins,et al.  Myc deletion rescues Apc deficiency in the small intestine , 2007, Nature.

[18]  M. Tallman,et al.  The Myelodysplastic Syndromes: Help Is On The Way! , 2007 .

[19]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[20]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[21]  R. Tibshirani,et al.  Differential Gene Expression Profiles in CD34+ Myelodysplastic Syndrome Marrow Cells. , 2005 .

[22]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Greenberg Myelodysplastic Syndromes: Pathogenetic mechanisms underlying myelodysplastic syndromes , 2005 .

[24]  S. Kajigaya,et al.  Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. , 2004, Blood.

[25]  T. Golub,et al.  Genomic approaches to hematologic malignancies. , 2004, Blood.

[26]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[27]  Y. Yamashita,et al.  DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome , 2003, British journal of haematology.

[28]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[29]  P. Khatri,et al.  Global functional profiling of gene expression ? ? This work was funded in part by a Sun Microsystem , 2003 .

[30]  P. Khatri,et al.  Global functional profiling of gene expression. , 2003, Genomics.

[31]  David Botstein,et al.  SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data , 2003, Nucleic Acids Res..

[32]  H Phillip Koeffler,et al.  Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34 , 2002 .

[33]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Menssen,et al.  Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  Y. Yamashita,et al.  Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. , 2001, Blood.

[37]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  N. Kenmochi,et al.  A complete map of the human ribosomal protein genes: assignment of 80 genes to the cytogenetic map and implications for human disorders. , 2001, Genomics.

[39]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.

[40]  David Botstein,et al.  The Stanford Microarray Database , 2001, Nucleic Acids Res..

[41]  I. Dokal,et al.  Dyskeratosis congenita in all its forms , 2000, British journal of haematology.

[42]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[43]  F. Marincola,et al.  High-fidelity mRNA amplification for gene profiling , 2000, Nature Biotechnology.

[44]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[47]  I. Pryme,et al.  Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts. , 1998, Leukemia research.

[48]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[49]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[50]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells , 1996 .

[51]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.

[52]  E. Wunders Hematopoietic stem cells : the Mulhouse manual , 1994 .

[53]  R. Abramson,et al.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Galton The myelodysplastic syndromes. , 1987, Clinical and laboratory haematology.